Exelixis (EXEL) Receives Price Target

Exelixis (EXEL) : The most positive equity analysts on Exelixis (EXEL) expects the shares to touch $12, whereas, the least positive believes that the stock will trade at $8 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $10.67 with an expected fluctuation of $2.31 from the mean.

Exelixis (EXEL) : Zacks Investment Research ranks Exelixis (EXEL) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.


Also, Stifel Nicolaus maintains its view on Exelixis (NASDAQ:EXEL) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Stifel Nicolaus raises the price target from $10 per share to $12 per share on Exelixis . The rating by the firm was issued on August 4, 2016.

Exelixis (NASDAQ:EXEL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.13 and $11.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.37. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.35, notching a gain of 1.79% for the day. The total traded volume was 3,869,528 . The stock had closed at $11.15 on the previous day.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.